CommercialPrior AuthHigh impact
08.00.75q, Erythropoiesis-Stimulating Agents (ESAs)
Independence Blue Cross·Hematology, Oncology, Nephrology +1 more·Medical Policy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.75q has been updated with changes to medical necessity criteria and/or medical coding for Erythropoiesis-Stimulating Agents (ESAs). The specific details of the criteria and coding changes are not provided in the available policy information, requiring the billing team to review the full policy text at the source URL to understand exact requirements.
Action Required
By November 17, 2025: Billing team must access the full policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=11&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-75q to identify specific ESA-related billing codes affected. Update billing system rules and prior authorization requirements based on new medical necessity criteria. Providers must be notified of any documentation changes required for ESA claims. Implement changes in EHR encounter templates and billing software. Claims submitted without compliance to new criteria may face denials or rejections.